

North Central Cancer Treatment Group

N054C; Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients with Metastatic Colorectal Cancer

Status Change – August 25, 2009

NOTICE OF STATUS CHANGE

This study is temporarily suspended to patient accrual effective Tuesday, August 25, 2009. Patient entry will not be permitted after August 24, 2009 at 4:30 CST until further notification is issued.

The study is temporarily suspended to patient accrual pending review of adverse events based on the current toxicity stopping rules. Four of the first 18 patients on the study have experienced Grade 3 or greater adverse events possibly related to treatment. According to the protocol design, the study is temporarily suspended to accrual to evaluate these occurrences.

Patients currently enrolled should continue treatment according to the protocol. Notification will be sent when the study is re-opened.

Please retain this notice with the protocol.